Abstract P4-13-15: Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experience

R. Forcignanò(Ospedale Vito Fazzi), Mariangela Ciccarese, Guido Giordano(University of Foggia), Luciana Petrucelli(Ospedale Vito Fazzi), Maria Morritti(Casa Sollievo della Sofferenza), Elisabetta De Matteis(Unknown), Antonio Cusmai(Radiation Oncology Institute), Nicla La Verde(ASST Fatebenefratelli Sacco), Alessandra Fabi(Agostino Gemelli University Polyclinic), Evaristo Maiello(Casa Sollievo della Sofferenza), Assunta Tornesello(Casa Sollievo della Sofferenza), Marianna Giampaglia(Ospedale San Carlo), V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), Serena Campidoglio(ASST Fatebenefratelli Sacco), Antonio Febbraro(Fatebenefratelli Hospital), L. Lupo(Casa Sollievo della Sofferenza), Francesco Giotta(Istituto Tumori Bari), ME Cazzaniga(Casa Sollievo della Sofferenza), Gennaro Palmiotti(Radiation Oncology Institute), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), S. Romito(Ospedali Riuniti di Foggia), V.E. Chiuri(Casa Sollievo della Sofferenza), C. Scavelli(ASST Fatebenefratelli Sacco), Giuseppe Cairo(Ospedale Vito Fazzi)
Cancer Research
February 15, 2016
10.1158/1538-7445.sabcs15-p4-13-15
Cited by 0

Related Papers

Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|333
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
|Journal of Clinical Oncology|2022|231
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177